TY - JOUR
T1 - Dose-related effect of triazolam on postural sway
AU - Robin, Deborah W.
AU - Hasan, Samer S.
AU - Lichtenstein, Michael J.
AU - Shiavi, Richard G.
AU - Wood, Alastair J.J.
PY - 1991/5
Y1 - 1991/5
N2 - Measurement of clinically relevant benzodiazepine drug effects at hypnotic and anxiolytic doses has been difficult because most measures are subjective, difficult to interpret, or relate to anesthetic doses. A potentially useful measure of drug effect is postural sway, which is a manifestation of the corrective mechanisms associated with the maintenance of upright posture. Postural sway was measured over 8 hours, with a biomechanics force platform, in six healthy male volunteers who received triazolam, 0.125, 0.250, or 0.375 mg, or placebo in a randomized double-blind study. Our results show a dose-dependent increase in postural sway measured as the elliptical area or the 95% confidence ellipse for the area covered by the subjects' sway. After triazolam, 0.250 and 0.375 mg, the area under the sway-time curve and peak effect increased significantly compared with placebo (p < 0.05). The number of losses of balance when subjects stood on one foot also showed a significant increase with increased dose (p < 0.05). The rate of loss of balance was positively correlated with the extent of postural sway (r = 0.802; p < 0.001). The extent of sway when the subjects were drug free predicted this increase in a subject's postural sway with triazolam. Thus at hypnotic or anxiolytic doses of triazolam, computer-assisted force platform measures of sway provide a clinically relevant measure of drug effect. Measurement of drug-induced postural sway may be useful in persons at risk for falls, such as the elderly.
AB - Measurement of clinically relevant benzodiazepine drug effects at hypnotic and anxiolytic doses has been difficult because most measures are subjective, difficult to interpret, or relate to anesthetic doses. A potentially useful measure of drug effect is postural sway, which is a manifestation of the corrective mechanisms associated with the maintenance of upright posture. Postural sway was measured over 8 hours, with a biomechanics force platform, in six healthy male volunteers who received triazolam, 0.125, 0.250, or 0.375 mg, or placebo in a randomized double-blind study. Our results show a dose-dependent increase in postural sway measured as the elliptical area or the 95% confidence ellipse for the area covered by the subjects' sway. After triazolam, 0.250 and 0.375 mg, the area under the sway-time curve and peak effect increased significantly compared with placebo (p < 0.05). The number of losses of balance when subjects stood on one foot also showed a significant increase with increased dose (p < 0.05). The rate of loss of balance was positively correlated with the extent of postural sway (r = 0.802; p < 0.001). The extent of sway when the subjects were drug free predicted this increase in a subject's postural sway with triazolam. Thus at hypnotic or anxiolytic doses of triazolam, computer-assisted force platform measures of sway provide a clinically relevant measure of drug effect. Measurement of drug-induced postural sway may be useful in persons at risk for falls, such as the elderly.
UR - http://www.scopus.com/inward/record.url?scp=0025891977&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025891977&partnerID=8YFLogxK
M3 - Article
C2 - 2029831
AN - SCOPUS:0025891977
SN - 0009-9236
VL - 49
SP - 581
EP - 588
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
IS - 5
ER -